Budget impact model of rituximab after failure of one or more TNFα inhibitor therapies in the treatment of rheumatoid arthritis

Joint Bone Spine

Volumn 75, Issue 6, 2008, Pages 688-695

  Launois, Robert ^a   Payet, Stéphanie ^a   Saidenberg Kermanac'h, Nathalie ^b,c,d   Francesconi, Camille ^a   França, Lionel Riou ^a   Boissier, Marie Christophe ^b,c,d  

^a REES France   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d AVICENNE HOSPITAL   (France)

Author keywords

Budget impact; Costs; Rheumatoid arthritis; Rituximab; TNF inhibitors

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; BUDGET; COST CONTROL; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HUMAN; PROBABILITY; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG UTILIZATION; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; RHEUMATOLOGY; SENSITIVITY AND SPECIFICITY;

EID: 57049113843     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2008.04.012     Document Type: Article

References (30)

1. Kahn M.F. Can we estimate the incidence, prevalence and outcomes of rheumatoid arthritis in France?. Joint Bone Spine 71 (2004) 95-97
2. Maini R.N., Taylor P.C., Szechinski J., et al. Double blind randomized controlled clinical trial of the interleukin-6 receptor agonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 (2006) 2817-2829
3. Genovese M.C., Becker J.C., Schiff M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353 (2005) 1114-1123
4. Edwards J.C.W., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with Rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
5. Saraux A., Devauchelle V., Jousse S., et al. Rituximab in rheumatic diseases. Joint Bone Spine 74 (2007) 4-6
6. Smolen J.S., Aletaha D., Koeller M., et al. New therapies for treatment of rheumatoid arthritis. Lancet 370 (2007) 1861-1874
7. Falgarone G., Duclos M., and Boissier M.C. TNFα antagonists in rheumatoid arthritis patients seen in everyday practice. Joint Bone Spine 74 (2007) 523-526
8. Rat A.C., and Boissier M.C. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine 71 (2004) 518-524
9. Maravic M., Bergé C., Daurès J.P., et al. Survey of practices regarding management of early rheumatoid arthritis by rheumatologists in France. Clin Exp Rheumatol 22 (2004) 319-327
10. Maravic M., Bergé C., Daurès J.P., et al. Practices for managing a flare of long-standing rheumatoid arthritis: survey among French rheumatologists. Clin Exp Rheumatol 23 (2005) 36-42
11. http://www.has-sante.fr/portail/display.
12. Lu G., and Ades A.E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23 (2004) 3105-3124
13. Cohen S.B., Emery P., Greenwald M.W., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006) 2793-2806
14. Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 (2006) 1390-1400
15. Weinblatt M.E., Kremer J.M., Bankhurst A.D., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 (1999) 253-259
16. Bathon J.M., Martin R.W., Fleischmann R.M., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343 (2000) 1586-1593
17. Moreland L.W., Schiff M.H., Baumgartner S.W., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130 (1999) 478-486
18. Klareskog L., van der Heijde D., de Jager J.P., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
19. Keystone E.C., Kavanaugh A.F., Sharp J.T., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004) 1400-1411
20. van de Putte L.B.A., Atkins C., Malaise M., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63 (2004) 508-516
21. Lipsky P.E., van der Heijde D.M., St Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 (2000) 1594-1602
22. St Clair E.W., van der Heijde D.M., and Smole J.S. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004) 3432-3443
23. Westhovens R., Yocum D., Han J., et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54 (2006) 1075-1086
24. Kristensen L.E., Saxne T., Nilsson J.A., et al. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 8 (2006) R174
25. Weinblatt M.E., Keystone E.C., Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (2003) 35-45
26. Geborek P., Crnkic M., Peterson I.F., et al. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 61 (2002) 793-798
27. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41 (1998) 1552-1563
28. Kavanaugh A. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?. Nat Clin Pract Rheumatol 2 (2006) 346-347
29. Kobelt G., Eberhardt K., and Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: cost and outcomes in a follow-up study of patients with RA treated with etanercept of infliximab in southern Sweden. Ann Rheum Dis 63 (2004) 4-10
30. Fautrel B., Woronoff-Lemsi M.C., Ethgen M., et al. Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France. Joint Bone Spine 72 (2005) 550-556